What is the recommended treatment for schizophrenia?

Schizophrenia Treatment

Initiate treatment with an antipsychotic medication selected collaboratively with the patient based on side-effect profile, with first-line options including risperidone, paliperidone, olanzapine (with metformin), or aripiprazole, and switch to clozapine after two failed antipsychotic trials of adequate dose and duration. 1

Initial Pharmacological Treatment

Start antipsychotic medication when psychotic symptoms persist for ≥1 week with associated distress or functional impairment 1. The choice should be made through shared decision-making, prioritizing the individual's tolerance for specific side effects rather than arbitrary class distinctions (first-generation vs. second-generation) 1.

First-Line Antipsychotic Selection

• Trial duration: Maintain therapeutic dose for minimum 4 weeks before declaring inadequate response 1
• Dosing strategy: Use therapeutic doses from the outset—underdosing is a common pitfall
• Monitoring: Assess for efficacy and side effects throughout treatment 2

Key caveat: The distinction between "first-generation" and "second-generation" antipsychotics should not guide drug selection, as these categories lack pharmacological or clinical validity 1. Instead, select based on individual receptor profiles and side-effect vulnerabilities.

Treatment Algorithm for Inadequate Response

After First Antipsychotic Failure (4 weeks at therapeutic dose)

Switch to a different antipsychotic with a distinct pharmacodynamic profile 1:

• If started on D2 partial agonist (aripiprazole): switch to amisulpride, risperidone, paliperidone, or olanzapine
• Use gradual cross-titration based on half-life and receptor binding characteristics 1

After Second Antipsychotic Failure (4 weeks at therapeutic dose)

Reassess diagnosis and contributing factors (substance use, medical conditions) before proceeding 1. If schizophrenia diagnosis confirmed:

Initiate clozapine 1, 2—this is a strong recommendation (1B evidence) from multiple guidelines. Clozapine is the only medication with proven efficacy in treatment-resistant schizophrenia and should not be delayed further.

Clozapine Dosing Strategy

• Co-prescribe metformin from initiation to prevent weight gain 1
• Target plasma level: ≥350 ng/mL initially 1
• If inadequate response at 12 weeks: increase to achieve 350-550 ng/mL 1
• Above 550 ng/mL: Number needed to treat is 17; consider only after discussion with patient/family, and add prophylactic lamotrigine due to seizure risk 1

Clozapine Augmentation Options

If positive symptoms persist despite adequate clozapine levels:

• Amisulpride augmentation
• Aripiprazole augmentation
• Electroconvulsive therapy 1

For persistent negative symptoms on clozapine: add an antidepressant 1

Special Indications for Clozapine

Beyond treatment resistance, clozapine has specific strong indications:

• Substantial suicide risk despite other treatments (1B recommendation) 2
• Persistent aggressive behavior despite other treatments (2C suggestion) 2

Long-Acting Injectable Antipsychotics

Consider LAI formulations for patients with poor adherence history or patient preference (2B suggestion) 2. Recent evidence shows LAIs reduce treatment discontinuation by 36% in patients with comorbid substance use disorder compared to oral formulations 3, making them particularly valuable in this high-risk subgroup.

Maintenance Treatment

Continue antipsychotic medication indefinitely once symptoms improve (1A recommendation) 2. Maintenance treatment reduces relapse from 61% to 24% at one year 4, and provides benefits beyond relapse prevention including:

• Improved quality of life 4
• Better social functioning 4
• Higher rates of sustained remission (36% vs 26%) 4

Preferentially continue the same antipsychotic that achieved symptom control (2B suggestion) 2.

Essential Psychosocial Interventions

Pharmacotherapy must be combined with evidence-based psychosocial treatments (all 1B recommendations) 2:

• First-episode psychosis: Coordinated specialty care program
• Cognitive-behavioral therapy for psychosis (CBTp): For all patients
• Psychoeducation: Universal provision
• Supported employment services: To improve vocational outcomes
• Assertive community treatment: For those with poor engagement history, frequent relapses, or social disruption
• Family interventions: When ongoing family contact exists (2B suggestion)

Side Effect Management

Movement Disorders

• Acute dystonia: Anticholinergic medication (1C recommendation) 2
• Parkinsonism: Lower dose, switch antipsychotic, or add anticholinergic (2C suggestion) 2
• Akathisia: Lower dose, switch antipsychotic, add benzodiazepine, or add beta-blocker (2C suggestion) 2
• Tardive dyskinesia (moderate-severe): VMAT2 inhibitor (1B recommendation) 2

Metabolic Effects

Antipsychotics increase risk of weight gain (9% vs 6% with placebo, NNH=25) 4. Proactive metabolic monitoring and metformin co-prescription with high-risk agents (particularly clozapine and olanzapine) is essential 1.

Critical Clinical Pitfalls

1. Delaying clozapine: Do not cycle through multiple non-clozapine antipsychotics after two adequate trials have failed
2. Inadequate trial duration: Full 4-week trials at therapeutic doses are required before switching (12 weeks for clozapine)
3. Premature discontinuation: Maintenance treatment prevents relapse and improves long-term outcomes—discontinuation should be rare
4. Neglecting psychosocial interventions: Medication alone is insufficient; structured psychosocial programs are evidence-based requirements
5. Ignoring adherence barriers: Consider LAI formulations proactively, especially with substance use comorbidity